Introduction
Natural interferon-β (IFN-β) is produced by most cells in response to viral infections or an exposure to other biologics. IFN-β is implicated in antiviral, antiproliferative and immunomodulatory activities. Several recombinant human interferon-β-1a (IFN-β-1a) preparations are commercially available for the treatment of relapsing forms of multiple sclerosis (Revel 2003) . The biological effects are mediated through interactions with heterodimeric interferon receptor constituted by IFNAR1 and IFNAR2. Receptor binding is a sequential process, with the IFN-β first binding to the higher affinity IFNAR2, followed by the recruitment of IFNAR1, to form the ternary complex, with consequent receptor and cellular activation (Strunk et al. 2008) . During the formation of the ternary complex, the IFN-β binding induces a substantial IFNAR1 conformational change found essential for the signal activation (Strunk et al. 2008) . Human type I interferons (IFN-β, IFN-ε, IFN-κ, IFN-ω and 12 subtypes of IFN-α) signal through the same cell-surface receptors, IFNAR1 and IFNAR2, distinctively evoking different physiological responses (Lavoie et al. 2011; Thomas et al. 2011) . The differential activities of type I interferons are modulated by the stability of the ternary complex (Kalie et al. 2008 ) and a key role is played by the functional plasticity of IFNAR1 in controlling the IFN-β signaling (Thomas et al. 2011) . Among the type I interferons, IFN-β seems to play a unique physiological role and is especially potent in activity requiring long-term stimulation (Gough et al. 2012) .
IFN-β is a 166 amino acid glycoprotein with a single N-linked carbohydrate chain on Asn 80 residue. Commercial IFN-β-1a preparations are made up of a distribution of all corefucosylated glycoforms differing in sialylation and antennarity degree. The most abundant is the biantennary, disialylated corefucosylated IFN-β glycoform (Conradt et al. 1987; Orru et al. 2000) . For IFN-β, it is generally accepted that the carbohydrate moiety is mainly involved in promoting solubility and stability of the protein. However, the exact role of each IFN-β glycoform is still unknown.
In a recent study on the IFN-β signaling pathway in a murine model, the authors showed that the glycosylation consensus sequence (NET), conserved between murine and human IFN-β, is part of the contact surface with IFNAR1 (de Weerd et al. 2013) . Although the authors did not directly investigate the role of glycosylation, the presence of a bulky glycosylation structure at this residue most probably has the potential to impact the interaction with the IFNAR1 receptor.
Given the presence of a high number of surface-exposed hydrophobic residues close to the glycosylation site (Karpusas et al. 1997) , it was suggested that the carbohydrate chain shields exposed hydrophobic residues from the solvent in order to avoid aggregation and increase solubility (Conradt et al. 1987; Karpusas et al. 1997; Runkel et al. 1998) . Terminal sialic acid was demonstrated to affect pharmacokinetics and biologic activities (Kasama et al. 1995) . The lack of glycosylation leads to an increased level of aggregation, sensitivity to thermal denaturation and a substantial decrease in the biological activity Dissing-Olesen et al. 2008 ). Deglycosylation did not cause any major change in the secondary and the tertiary structures , while the in vitro bioactivity of the unglycosylated IFN-β was found to be 10-14 times lower than that of the glycosylated forms Antonetti et al. 2002) . Core fucose of the IFN-β carbohydrate chain has been reported to stabilize the IFN-β structure through two H-bonds with Asn 86 and Gln 23 residues of IFN-β . A remarkable feature is the close integration of the carbohydrate chain in the tertiary structure of the IFN-β molecule . Mutational analyses identified the main receptor binding regions on opposite surfaces of the IFN-β molecule Runkel et al. 2000) and the IFN-β-1a crystal structure has revealed the existence of an asymmetric unit made up of two conformers (A and B) (Karpusas et al. 1997) .
The in vivo role of the terminal sialic acid, the core fucosylation and the complete deglycosylation was studied using the Mx biomarker response (Dissing-Olesen et al. 2008) . The IFN-β deglycosylation depleted the bioactivity while IFN-β defucosylation showed to have no impact. The desialylation of IFN-β resulted in depleted bioactivity after 48-h at 37°C, whereas after a 2-h incubation period with sialidase, this was not the case, suggesting that sialic acid has no direct impact on the IFNAR1/IFNAR2 binding but instead reduces its susceptibility to heat-induced loss of activity (Dissing-Olesen et al. 2008) . The same study revealed that de-fucosylation did not have a negative impact on the bioactivity even after prolonged incubation (48 h), while a previous study indicated a stability promoting effect of the core fucose (Karpusas et al. 1997; Runkel et al. 1998 ).
In the following study, we report a comprehensive characterization of the main IFN-β glycoforms. The glycoforms were obtained by a charge-based enrichment from drug substance material carrying a heterogeneous pool of glycoforms typical for recombinant expression in Chinese hamster ovary (CHO) cells. To our knowledge, this is the first study reporting the isolation and extensive physicochemical and in vitro biological activity characterization of the major individual IFN-β 1a glycoforms.
Results

Glycoform enrichment
The chromatographic profile of the cation-exchange (CEX) fractionation resulted in a number of partially overlapping peaks with a gradual decrease in overall sialic acid content and antennarity, correlating with the decrease of the overall molecular charge of the IFN-β molecule. From the collected fractions, those with a high purity (as judged from the MS-signal) were selected for further characterization.
Enzymatic desialylation of IFN-β-1a
As a control, a drug substance sample was also desialylated by enzymatic treatment. The degree of desialylation was verified by electrospray ionization-mass spectrometry (ESI-MS) analysis. The sample was found to be completely desialylated (see Figure 1 ). Under the given conditions, the enzymatic desialylation did not cause significant aggregation and the monomeric purity remained >95% (see Table I ).
Physicochemical characterization
The physicochemical characterization data of these IFN-β-enriched glycoforms are reported in Table I and the corresponding ESI-MS spectra in comparison with the starting material are shown in Figure 1 . These fractions mostly represent glycoforms described in the European Pharmacopoeia monograph (European Pharmacopoeia 7.8, Nr. 1639E, Interferon beta 1a concentrated solution) referred to as forms A-E. The most abundant glycan found in the unfractionated start material is a biantennary complex type, disialylated core-fucosylated structure. Linkage analysis by sequential exoglycosidase treatment (results not shown), performed previously on drug substance derived from the same working cell bank, has confirmed that the linkages of this main glycan species corresponds to those reported by Conradt et al. (1987) .
All tested samples showed a monomer content >95%. The unfolding temperatures of the fractions were largely similar and no significant differences were observed in comparison with the unfractionated starting material. It is interesting to note that, under the sample conditions used ( pH 3.8) the desialylated control showed no significant differences in terms of melting temperature or monomeric purity compared either with the unfractionated start material or the obtained fractions. This indicates that the desialylated molecule has a stability which is comparable with the sialylated start material.
Biological characterization
The biological characterization of the enriched fractions in comparison with the start material and desialylated control is reported in Figure 2 . With the exception of the Reporter Gene Assay (RGA), in all the in vitro tests performed, the responses of the individual glycoforms were positively correlated with the antennarity (see Figure 2) . Here, it is interesting to note that the desialylated unfractionated material showed a lower activity compared with the start material. Furthermore, fraction 7, a fully sialylated biantennary oligosaccharide, corresponding to the main glycoform of the unfractionated material, behaved in a very similar way.
Aggregation propensity
Aggregated IFN-β has been shown to exhibit a diminished bioactivity with respect to the monomeric form (Orru et al. 2000) ; therefore, it was decided to assess the aggregation propensity of the desialylated protein in regards to its sialylated form. The sodium dodecyl sulfate-polyacrylamide gel electrophoresis western blotting (SDS-PAGE WB) analysis after an incubation period at 37°C for 24 h can be seen in Figure 3 . After incubation, both at pH 3.8 and pH 7.2, the major part of the material remains in a monomeric state. At both of these tested pH values, the desialylated material shows a higher propensity to aggregate compared with the sialylated form. At pH 7.2, the aggregation levels are generally higher compared with the lower pH. Such differences however do not explain the lower activity of the desialylated IFN-β when compared with the start material.
Discussion
Recombinant IFN-β-1a preparations are made up of a distribution of core-fucosylated glycoforms differing in sialylation and antennarity degree. The most abundant is the biantennary, disialylated core-fucosylated IFN-β glycoform. In order to investigate the role of the IFN-β glycoform heterogeneity, i.e., different levels of branching (antennarity) and sialic acid content, a fractionation of the major IFN-β glycoforms was performed. The separation resulted in a stratification of the glycoforms according to their antennarity and sialic acid content. Due to the technical approach chosen, i.e., a charge-based separation of the glycoforms, the fractions with high antennarity level have also a high sialylation level.
Fractions that showed a reasonable purity of one of the major glycoforms described in the European Pharmacopoeia monograph were selected for further in-depth characterization by physicochemical (ESI-MS, sialic acid content, thermal denaturation by circular dichroism (CD)) and biological methods (panel of in vitro bioassays). The results of the fractions were compared with those of the unfractionated IFN-β-1a start material. The latter was also tested after enzymatic desialylation in order to gain some insight into the isolated effect of sialylation. With the exception of the Reporter Gene Assay, in all of the in vitro tests the responses of the fractions were positively correlated with the antennarity degree.
Surprisingly, although representing the major IFN-β glycoforms in commercial IFN-β-1a preparations, the biantennary IFN-β glycoforms (both disialo 2A2S1F and monosialo 2A1S1F, corresponding to fractions 7 and 9, respectively) showed the lowest relative activity, which approximately corresponded to that of fully desialylated start material. This suggests that antennarity is the predominant parameter determining or sustaining the IFN-β bioactivity. The results of the enriched fractions are compared with the unfractionated start material and a desialylated control. Abbreviations used for glycan denomination: 2A, biantennary complex type oligosaccharide; 3A, triantennary complex type oligosaccharide; 4A, tetraantennary complex type oligosaccharide; 0S, non-sialylated; 1S, monosialylated; 2S, disialylated; 3S, trisialylated; 1F, fucosylated. Glycan structures are annotated in symbol form following the glycan nomenclature established by the Consortium for Functional Glycomics ( http://www. functionalglycomics.org/glycomics/publicdata/glycoprofiling.jsp) using the following monosaccharide key. Red triangle, fucose; green circle, mannose; yellow circle, galactose; blue square, N-acteylglucosamine; purple diamond, N-actetylneuraminic acid.
In vitro biological characterization of IFN-β-1a glycoforms
Two recent studies investigating the role of the IFN-β glycosylation on bioactivity produced important and apparently contrasting results. Dissing-Olesen et al. compared the IFN-β in vivo bioactivity of completely desialylated IFN-β-1a versus a sialylated control (Dissing-Olesen et al. 2008 ) and the authors concluded a stabilizing role of the sialic acid residues on the heat-labile IFN-β during prolonged incubation at 37°C. In addition, the authors hypothesized that specific modulations of the glycan moiety (glycoengineering), e.g., hypersialylation of the galactose residues of the biantennary structure or through increased branching (i.e., tri-or tetraantennary structures with more terminating sialic acid residues as a result), may result in increased stability of the native protein. Instead, (Sakamoto et al. 2012 ) investigated the biological activity of homogeneous (through chemical synthesis) biantennary complex type IFN-β oligosaccharide structures corresponding to sialylated and nonsialylated biantennary glycoforms (2A2S1F and 2A0S1F). The authors found that these had equivalent in vitro antitumor activity, which suggests, at least for this antennarity level, that sialylation is not the predominant factor determining bioactivity. The authors found also that the bioactivities of these forms were lower when compared with CHO-or human fibroblastderived IFN-β carrying a heterogeneous (both in terms of antennarity and sialylation) distribution of glycans.
Despite those seemingly contrasting findings of the two previous studies, our results were found to be in line with both and add complementary data shedding additional light on the role of glycosylation with respect to IFN-β bioactivity. In our experiments, the lower in vitro activity of the desialylated control in comparison with the unmodified start material (observed in those bioassays that use a prolonged incubation time, i.e., longer than 2 h) is in line with the in vivo data by Dissing-Olesen. Moreover, the fact that the RGA (i.e., the bioassay with the shortest incubation time of 2 h) does not show the same trend (i.e., a correlation of the bioassay response with the antennarity level) as the other in vitro bioassays, corresponds to the results of Dissing-Olesen who found that a loss in activity in the desialylated sample was observed only after prolonged incubation times but not with shorter ones, i.e., 2 h at 37°C (Dissing-Olesen et al. 2008) as used in the RGA test within our case studies. Analogous to the findings of Sakamoto et al., we have found that a predominantly 2A2S1F fraction (fraction 7) and 2A0S1F ( predominant species in the desialylated control) show an equivalent bioactivity, which, however, is lower than the unfractionated, heterogeneous start material. This may indicate that the stability promoting effect of sialic acid is evident mainly on tri-and tetraantennary and less pronounced on biantennary glycoforms. This finding also supports the hypothesis put forward by Dissing-Olesen et al. that increased branching/sialylation may result in an apparent increase in the IFN-β bioactivity. The individual effects of sialylation and antennarity should be further investigated, e.g., by fractionating the glycoforms first by antennarity degree and then desialylate them enzymatically.
One could expect that potential instabilities of some glycoforms should have accrued already in the conditioned media of the CHO cells and during purification and processing. However, our thermal denaturation data indicate equivalent thermal stability at pH 3.8 for the different glycoforms. Therefore, such accrued instabilities may be reversible as a function of pH and result in a homogenous bioactivity population of the different glycoforms after expression, purification and storage at pH 3.8. In addition, the molecule may be protected in the CHO cell culture environment by stabilizing agents which include surfactants commonly used in cell culture processes. For example, a stabilizing effect on IFN-β-1a has been observed for the surfactant Poloxamer (Dissing-Olesen et al. 2008) .
In a previous study Rodriguez et al. showed that IFN-β has a tendency to aggregate when incubated at 37°C. However, the rate of aggregation of glycosylated IFN-β was found to be lower than that of the non-glycosylated protein (Rodriguez et al. 2010) . As IFN-β aggregates do not form the ternary complex with IFNAR1 and IFNAR2 required for the signal transduction, the observed decrease of the in vitro bioactivity may be attributed to a gradual increase of aggregation levels over time. In order to qualitatively verify the aggregation propensity, SDS-PAGE WB analysis was performed comparing fully desialylated IFN-β and an untreated control after incubation for 24 h at 37°C at pH 7.2 and pH 3.8 (see Figure 3 ). This incubation time was chosen based on the findings of Rodriguez et al. (2010) who observed stable levels of aggregates after 24 h. The results confirmed that the desialylated material has a higher propensity to aggregate (in both pH 3.8 and pH 7.2), and that the overall aggregation level at pH 7.2 is higher compared with the lower pH. In any case, aggregation occurs at low levels and the major portion of the material remains in a monomeric form. Therefore, the low aggregate levels observed cannot fully explain the lower activity observed in our in vitro data as well as a complete activity loss of the desialylated IFN-β previously observed, e.g., after an incubation time of 48 h at 37°C, by Dissing-Olesen et al. (2008) . This implies that additional aspects may need to be taken into consideration, such as conformers or misfolded IFN-β molecules as proposed in studies by Bobst et al. (2008) and Karpusas et al. (1998) , which may exhibit a lower activity.
The impact of glycosylation on IFN-β stability had previously been investigated by thermal denaturation experiments and the unfolding temperature of glycosylated IFN-β was found to be 4-5°C higher when compared with the deglycosylated molecule. The authors concluded that glycosylation is an important factor when regarded to solubility, stability, and consequently, activity ). In our case study, no significant differences in thermal stability were observed among the fractions containing different sialylation and antennarity levels. However, it should be noted here that in our experiments the samples were tested at pH 3.8 (i.e., the pH value of the drug substance formulation), while Runkel et al. (1998) performed experiments at pH 7.2. As the stability of the different In vitro biological characterization of IFN-β-1a glycoforms glycoforms may be pH dependent, it cannot be ruled out that differences in terms of stability may be found at pH 7.2 and should be further investigated. Nevertheless, such data are indicative that at pH 3.8, as for example used for commercial IFN-β preparations, all glycoforms are equally stable with respect to thermal denaturation. Fig. 3 . SDS-PAGE WB analysis of native and desialylated IFN-β-1a-time course of 24-h incubation at 37°C at pH 3.8 and 7.2 (entire Gel in Panel A). In order to facilitate the comparison, arrows on the gel indicating the respective pairs of samples, i.e., time zero and incubation for 24 h at 37°C for the different conditions. Furthermore, these are shown in Panel B in the form of a cropped gel.
Oligosaccharides are known to have an impact on the IFN-β biological activity. However at present date, no direct interaction of the oligosaccharide chain residues with the IFNAR1 and the IFNAR2 receptors have been demonstrated. The X-ray structure of the IFN-β molecule shows that the carbohydrate chain projects away from the IFN-β core structure (Karpusas et al. 1997) . Considering that a typical oligosaccharide dimension is estimated to be roughly the size of an IgG domain (Dwek et al. 1995; Sakamoto et al. 2012) , their dynamics as well as the fact that the IFNAR1 and the IFNAR2 binding regions have been identified on opposite surfaces of the IFN-β molecule (Runkel et al. 2001) , it cannot be ruled out that the glycan structure modulates to some extent the interaction with the receptors or the conformational changes associated with the ternary complex and required for signaling. Nevertheless, a direct impact of the total sialic acid content and antennarity on the receptor interaction seems unlikely as observed from our RGA data in which no significant differences were found among fractions and when compared with the desialylated control.
Considering the fairly short incubation time in the RGA assay (2 h) in comparison with other in vitro bioassays, these observations support the presumed role of the sialic acid on high antennarity glycoforms in reducing thermal lability during exposure at 37°C, as previously reported (Dissing-Olesen et al. 2008) .
Cells require very low levels of IFN-β and act very fast in order to clear viral infections in their initial stages. The antiproliferative activity, which is often linked with apoptosis and tissue damage, needs to be under stringent control in order to prevent any unnecessary damage (Strunk et al. 2008) . The functional plasticity of the IFN-β/IFNAR1/IFNAR2 ternary complex in controlling IFN-β signaling and the downregulation of the IFNAR1 and the IFNAR2 by IFN-β (Jaitin et al. 2006 ) indicate a fine-tuned mechanism to control the IFN-β activity. Glycosylation antennarity is therefore suggested as an additional mechanism under physiological conditions to sustain the IFN-β bioactivity. In this mechanism, all IFN-β glycoforms are initially biologically active as soon as these are expressed by cells. Then, under physiological conditions, depending on their antennarity and sialylation degree, these glycoforms may undergo inactivation at different rates. Moreover, the temporal in vivo activity profile of a preparation will therefore depend both on the glycoform distribution, i.e., the different retention of activity over time (as a function of antennarity), and the differences in clearance rate, e.g., due to sialylation degree. The proposed regulation mechanism of oligosaccharide chain antennarity adds a new prospective on the antennarity as part of a posttranslational modification code that allows the modulation of the biological properties of glycoproteins in response to environmental changes (Nussinov et al. 2012 ).
Materials and methods
Drug substance used for the characterization study Highly purified IFN-β-1a drug substance was supplied by Merck Serono S.A. (Switzerland). The production method employed recombinant expression of the protein in a CHO-K1-derived cell line using a commercial serum-free culture medium.
Crude harvests were processed through a series of chromatographic steps, including affinity, ion exchange, reversed-phase and size-exclusion chromatography. Final drug substance was formulated and stored in sodium acetate, pH 3.8. This buffer composition was selected on the basis of formulation development results.
Fractionation of IFN-β-1a by CEX chromatography
The preparation of the different IFN-β-1a glycoforms was carried out by CEX chromatography on a ProPac WCX 10 column 4 × 250 mm column (Dionex) connected to an Alliance HPLC system (Waters) equipped with a UV detector. As starting material, the IFN-β-1a drug substance (Merck Serono) was used after concentration by ultra-filtration (Amicon Ultra, Millipore) against sodium acetate buffer, pH 3.8. A gradient of 25-45% MES/LiCl (pH 5.0) was used at a flow rate of 1.0 mL/min. All experiments were performed at room temperature.
Protein content determination by reversed-phase ultra performance liquid chromatography Reversed-phase ultra performance liquid chromatography (RP-UPLC) analysis was performed on a Acquity UPLC BEH300 C4 1.7 µm 2.1 × 50 mm column (Waters) connected to a Acquity UPLC system (Waters) equipped with a TUV detector (Waters). A gradient of 70-40% acetonitrile was used at a flow rate of 0.45 mL/min. All experiments were performed at 25°C. Quantification was performed by the use of a calibration curve based on a reference house standard.
Enzymatic desialylation
Desialylation of IFN-β-1a drug substance was induced by enzymatic treatment with Sialidase A (Prozyme) according to the following procedure. Approximately 200 μg of IFN-β-1a drug substance were mixed with 0.6 mL reaction buffer 5× (Prozyme) and 15 μL of Sialidase A. The mixture was incubated for 1 h at 37°C. Subsequently, the sample was submitted to 5 buffer exchange cycles using sodium acetate buffer ( pH 3.8) employing Amicon Ultra filters with a molecular-weight cut-off of 10 kDa (Millipore). Prior to further analyses, the sample was stored at 4°C. Complete desialylation was verified by ESI-MS.
Sialic acid content determination The 1,2-diamino-4,5-methylenedioxybenzene (DMB·2HCl) Sialic Acid Release and Labeling Kit (Ludger, UK) was used to release and fluorescently label terminal sialic acid. The DMB-labeled sialic acid was analyzed by RP-UPLC and quantification was achieved by comparison with a calibration curve based on sialic acid standards (Ludger, UK).
ESI-MS whole molecule analysis
Prior to analysis, samples were ultra-filtrated and subsequently analyzed by means of direct infusion. The employed ESI-MS method is based on the method described in the European Pharmacopoeia monograph (Nr. 1639E, Interferon beta 1a concentrated solution) with adaptations for the employed instrument. The analyses were performed on an Orbitrap Mass Spectrometer (Thermo Scientific) with the following
In vitro biological characterization of IFN-β-1a glycoforms instrumental settings: Scan ES (+) from 100 to 2000 m/z with a resolution set at 100 000; scan time 1 microscan 500 ms; capillary temperature: 200°C; capillary voltage 35 V, tube lens 145 V. The calibration of the Orbitrap mass spectrometer is set at 5 ppm (m/z) of mass error, however, for highly multicharged ions if intact proteins, such as IFN-β-1a, the obtained average molecular-weight accuracy is 100 ppm. After the acquisition, the m/z spectra were semi-automatically deconvoluted using the Xtract software package (Thermo Scientific). The expected molecular weights were calculated on the basis of the amino acid sequence, the correct disulfide bridge, and the contribution of the attached oligosaccharide structure. The identities of the detected glycan moieties have been verified in previous more detailed studies involving HILIC-UPLC glycan profiling of fluorescently labeled glycan standards, sequential exoglycosidase digestions and fragmentation analysis (MS/MS).
Thermal unfolding by circular dichroism
The analyses were performed on a Jasco J-810 Spectropolarimeter equipped with a Peltier temperature controller PTC-423S (Jasco). Temperature scans (fixed wavelength, various temperatures) were performed under the following conditions: wavelength 222 nm; data pitch 1 nm; temperature range 30-80°C; heating rate 1°C/min, protein concentration 0.1 mg/mL in drug substance buffer (sodium acetate, pH 3.8).
Size-exclusion analysis
The monomeric purity of the samples was analyzed by sizeexclusion HPLC analysis on a Waters HPLC system (Waters) by using a TSK G2000 SWXL column (Toso Bioscience, Japan), elution buffer sodium acetate ( pH 3.8) containing sodium chloride.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis western blotting IFN-β-1a samples ( 0.37 mg/mL) were run under nonreducing conditions on ExcelGel SDS homogeneous 12.5% (GE Healthcare). After the separation protein, bands were blotted onto 0.22 µm Whatman nitrocellulose membranes (Sigma-Aldrich). The membranes were incubated first with a polyclonal Anti-Interferon-β Antibody antibody (Calbiochem AB 1431, EMD Millipore), diluted 1:40,000, and then with a biotinylated secondary antibody (Goat Anti-Rabbit IgG (H + L)-HRP Conjugate, Bio-Rad), diluted 1:30,000. IFN-β-1a immune activity was revealed using enhanced chemiluminescence (ECL RNP 2232, GE Healthcare). Coomassie Blue staining PhastGel Blue R (Sigma-Aldrich) was used for comparison purposes to detect the additional molecular-weight markers bands.
Antiviralactivity (WISH/VSV) assay
This assay is based on a method reported by Grossberg et al. (1986) and is described in the European Pharmacopoeia 5.0. Chapter 5.6: Assay of Interferons. Briefly, it measures the protection exerted by the IFN-β-1a on WISH cells against the cytopathic effect (CPE) of the vesicular stomatitis virus (VSV). At the end of the incubation time of 18-22 h, VSV suspension was added to each well and the plate was incubated for an additional 20-25 h at 37°C. The cells were then stained with MTT and the optical density (OD at 595 nm) in each well was measured by a multiwell scanning spectrophotometer.
Antiproliferative activity (WISH) assay
This assay is based on a method described by Grossberg et al. (1986) . It measures the ability of IFN-β-1a to inhibit the growth of WISH. In summary, the WISH cells were plated in each well of a 96-well microtiter plate containing IFN-β-1a in a range of concentrations and then incubated for 72 h at 37°C. At the end of incubation period, the cells were stained with MTT and the optical density (OD at 595 nm) was measured in each well by a multiwell scanning spectrophotometer.
Reporter gene assay
This assay is based on a method reported by Ronni et al. (1993) . Briefly, it measures the reporter gene expression (Luciferase) in the HepG2 cell line triggered by a specific IFN-β inducible promoter (Mx1). Transient transfected cells are plated in a 96-well plate which contained IFN-β-1a in a range of concentrations. After 2 h of incubation at 37°C, the cell lysis buffer (Britelite plus) was added to each well. Cells and IFN-β-1a samples are then incubated for 2 h at 37°C. At the end of the incubation time, the induced Luciferase is revealed by adding Britelite reagent and the light emitted is read by means of a luminometer.
A549/EMCV antiviral activity
This assay is based on a method reported by Grossberg et al. (1986) and is described in the European Pharmacopoeia 5.0. Chapter 5.6: Assay of Interferons. Briefly, this assay measures the antiviral activity of IFN-β-1a by its protection exerted on the A549 cells (human lung carcinoma cells) against the cytopathic effect of encephalomyocarditis virus (EMCV). In summary, the A549 cells were plated in a 96-well microtiter plate which contained the IFN-β-1a in a range of concentrations and then incubated for at least 6 h at 37°C. At the end of the incubation time, the medium was removed. EMCV suspension was added to each well and allowed to act for 1 h at 37°C. After 30 h of incubation at 37°C the cells were stained with Naphthol Blue Black and the OD at 620 nm was measured in each well by a multiwell scanning spectrophotometer.
Hs297T antiproliferative activity
This assay is based on a method described by Grossberg et al. (1986) . It determines the ability of IFN-β-1a to inhibit the growth of the Hs294T human melanoma cells. In summary, the Hs294T cells were plated in each well of a 96-well microtiter plate containing IFN-β-1a in a range of concentrations and then incubated for 96 h at 37°C. At the end of incubation period, the cells were stained with MTT and the optical density (OD at 595 nm) was measured in each well by a multiwell scanning spectrophotometer.
Immunomodulatory activity (MHC expression)
This assay is based on a method described by Grossberg et al. (1986) . The assay principle is based on the ability of IFN-β-1a to upregulate the major histocompatibility complex (MHC) class I expression on the A549 cells in a dose-related manner. The A549 cells are incubated with different concentrations of the INFβ-1a for 48 h at 37°C. Then, the cells are harvested by using trypsin/EDTA and the expression of the MHC class I is evaluated by FACS analysis using a FITC-conjugated anti-hMHC I antibody and expressed in terms of mean fluorescence intensity.
In vitro bioassay data normalization and assessment
The results of the individual samples (start material, fractions and desialylated control) are expressed as a biological response in relation to a standard sample run in parallel in each analytical session and set to be equal to 100%. The biological activity was derived from dose-response curves that were constructed on a mass basis using the protein content (mass per volume) determined for the individual fractions by RP-UPLC. Moreover, in order to facilitate their comparison, the relative response of each sample was normalized against the relative response of their corresponding start material.
